ABO Blood Group.
Dean L.
2012 Oct 1 [updated 2015 Jul 27]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–.
Shigellosis.
Niyogi SK.
J Microbiol. 2005 Apr;43(2):133-43.
Cholera: An Overview with Reference to the Syrian Outbreak.
Hraib M, Alaidi S, Jouni S, Saad S, Muna M, Alaidi N, Alshehabi Z.
Avicenna J Med. 2023 Sep 27;13(4):199-205. doi: 10.1055/s-0043-1775762. eCollection 2023 Oct.
Fowl cholera.
Christensen JP, Bisgaard M.
Rev Sci Tech. 2000 Aug;19(2):626-37. doi: 10.20506/rst.19.2.1236.
Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen.
Lassalle F, Al-Shalali S, Al-Hakimi M, Njamkepo E, Bashir IM, Dorman MJ, Rauzier J, Blackwell GA, Taylor-Brown A, Beale MA, Cazares A, Al-Somainy AA, Al-Mahbashi A, Almoayed K, Aldawla M, Al-Harazi A, Quilici ML, Weill FX, Dhabaan G, Thomson NR.
Nat Microbiol. 2023 Oct;8(10):1787-1798. doi: 10.1038/s41564-023-01472-1. Epub 2023 Sep 28.
Genetic susceptibility to cholera.
Levine MM, Nalin DR, Rennels MB, Hornick RB, Sotman S, Van Blerk G, Hughes TP, O'Donnell S, Barua D.
Ann Hum Biol. 1979 Jul-Aug;6(4):369-74. doi: 10.1080/03014467900003751.
Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, Kováč P, Xu P, LaRocque RC, Calderwood SB, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB, Qadri F, Ryan ET.
PLoS Negl Trop Dis. 2018 Apr 6;12(4):e0006376. doi: 10.1371/journal.pntd.0006376. eCollection 2018 Apr.
Immunogens of Pasteurella.
Confer AW.
Vet Microbiol. 1993 Nov;37(3-4):353-68. doi: 10.1016/0378-1135(93)90034-5.
Requirement of Peptidyl-Prolyl Cis/Trans isomerases and chaperones for cellular uptake of bacterial AB-type toxins.
Ernst K.
Front Cell Infect Microbiol. 2022 Aug 4;12:938015. doi: 10.3389/fcimb.2022.938015. eCollection 2022.
Strategies to Block Bacterial Pathogenesis by Interference with Motility and Chemotaxis.
Erhardt M.
Curr Top Microbiol Immunol. 2016;398:185-205. doi: 10.1007/82_2016_493.
